Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

NCT ID: NCT00301834

Last Updated: 2017-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-01-31
• Study Completion Date: 2011-09-30

Brief Summary

RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as fludarabine and busulfan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell, bone marrow , or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine together with methotrexate and methylprednisolone may stop this from happening.

PURPOSE: This phase II trial is studying how well giving alemtuzumab together with fludarabine and busulfan works when given before donor stem cell transplant in treating young patients with hematologic disorders.

Detailed Description

OBJECTIVES:

Primary

• Determine the engraftment rate with reduced toxicity ablative conditioning regimen comprising alemtuzumab, fludarabine, and busulfan followed by allogeneic stem cell transplantation in pediatric patients with stem cell defects, marrow failure syndromes, hemoglobinopathy, severe immunodeficiency syndromes (nonsevere combined immunodeficiency disorders), myelodysplastic syndromes, or myeloid leukemia.

Secondary

• Determine the acute reactions, incidence of infections, and rate of immune reconstitution in patients treated with this regimen.

OUTLINE: This is a multicenter study.

• Conditioning regimen: Patients receive alemtuzumab IV over 6 hours on days -12 to -10, high-dose busulfan IV over 2 hours 4 times daily on days -9 to -6, and fludarabine IV over 30 minutes on days -5 to -2.
• Allogeneic stem cell transplantation: Two days after the completion of conditioning regimen, patients undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation on day 0. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover.
• Graft-vs-host disease (GVHD) prophylaxis:

• Most transplantations (bone marrow or peripheral blood stem cell transplantation): Patients receive cyclosporine IV continuously beginning on day -1 until at least day 50 followed by a taper at either 2 months, 9 months, or 1 year in the absence of GVHD. Patients also receive methotrexate on days 1, 3, and 6.
• Umbilical cord blood transplantation: Patients receive cyclosporine as in most transplantations, and methylprednisolone IV twice daily on days 0-21 followed by a weekly taper.

After transplantation, patients are followed periodically for up to 20 years.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.

Conditions

Congenital Amegakaryocytic Thrombocytopenia; Diamond-blackfan Anemia; Leukemia; Myelodysplastic Syndromes; Severe Congenital Neutropenia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single arm - conditioning and transplant

Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m\*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m\*2 on day +1, 10 mg/m\*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.

Group Type: EXPERIMENTAL

alemtuzumab

Intervention Type: BIOLOGICAL

busulfan

Intervention Type: DRUG

cyclosporine

Intervention Type: DRUG

fludarabine phosphate

Intervention Type: DRUG

methotrexate

Intervention Type: DRUG

methylprednisolone

Intervention Type: DRUG

allogeneic bone marrow transplantation

Intervention Type: PROCEDURE

allogeneic hematopoietic stem cell transplantation

Intervention Type: PROCEDURE

peripheral blood stem cell transplantation

Intervention Type: PROCEDURE

umbilical cord blood transplantation

Intervention Type: PROCEDURE

Interventions

alemtuzumab

Intervention Type: BIOLOGICAL

busulfan

Intervention Type: DRUG

cyclosporine

Intervention Type: DRUG

fludarabine phosphate

Intervention Type: DRUG

methotrexate

Intervention Type: DRUG

methylprednisolone

Intervention Type: DRUG

allogeneic bone marrow transplantation

Intervention Type: PROCEDURE

allogeneic hematopoietic stem cell transplantation

Intervention Type: PROCEDURE

peripheral blood stem cell transplantation

Intervention Type: PROCEDURE

umbilical cord blood transplantation

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following hematologic conditions:

• Aplastic anemia with marrow aplasia, meeting all of the following criteria:

• Absolute neutrophil count < 500/mm^3
• Platelet and/or red cell transfusion dependent
• Chronic aplastic anemia, meeting all of the following criteria:

• Transfusion dependent
• Unresponsive to immunosuppressive therapy
• Alternative matched unrelated donor has been identified
• Congenital marrow failure syndrome, including any of the following (with closely matched related or unrelated donor):

• Primary red cell aplasia (Diamond-Blackfan syndrome)
• Congenital neutropenia (Kostmann's syndrome)
• Amegakaryocytic thrombocytopenia
• Congenital dyserythropoietic anemias
• Other severe acquired cytopenias in which a transplantation using a combined busulfan/cyclophosphamide conditioning regimen is indicated
• Hemoglobinopathy (with closely matched related or unrelated donor)

• β-thalassemia major
• Sickle cell anemia
• Hemoglobin E/β-thalassemia
• Severe immunodeficiency disease

• Chediak-Higashi disease
• Wiskott-Aldrich syndrome
• Combined immunodeficiency disease (Nezelof's)
• Hyper immunoglobulin M (IgM) syndrome
• Bare lymphocyte syndrome
• Chronic granulomatous disease
• Familial erythrohemophagocytic lymphohistiocytosis
• Other stem cell defects (e.g., osteopetrosis)
• Severe immune dysregulation/autoimmune disorders

• Achieved a transient response to prior immunosuppressive therapy
• Chronic myelogenous leukemia

• Disease in first chronic phase
• Acute myeloid leukemia

• Disease in first remission
• Myelodysplastic syndromes
• Inborn errors of metabolism
• Histiocytosis
• No severe combined immunodeficiency disease
• Matched related or unrelated donor available by high resolution DNA typing

• Related donor, meeting both of the following criteria:

• Matched at both human leukocyte antigen (HLA)-Drβ1 alleles
• No more than 1 mismatch at the 4 HLA-A and -B alleles
• Unrelated donor, meeting 1 of the following criteria:

• Marrow matched at both HLA-Drβ1 alleles AND no more than 1 mismatch at the 4 HLA-A and -B alleles
• Umbilical cord blood matched at 5/6 HLA-A, -B, and -DRβ1 alleles with at least 1 -DRβ1 match AND there are ≥ 3x10^5 CD34+ (Cluster of differentiation 34-positive) cells per kg body weight of recipient available at the time of cryopreservation

PATIENT CHARACTERISTICS:

• Cardiac ejection fraction ≥ 27%
• Creatinine clearance ≥ 50 mL/min by 24-hour urine collection or glomerular filtration rate
• DLCO (diffusion capacity of lung for carbon monoxide) ≥ 50% of predicted (corrected for anemia/lung volume)

PRIOR CONCURRENT THERAPY:

• No prior transplantation for leukemia from which patient remains engrafted and alemtuzumab is not needed as part of the conditioning regimen

• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

University of California, San Francisco

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Morton J. Cowan, MD

Role: STUDY_CHAIR

University of California, San Francisco

Locations

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

Madison, Wisconsin, United States

Countries

United States

Other Identifiers

UCSF-04152

Identifier Type: OTHER

Identifier Source: secondary_id

UCSF-00452

Identifier Type: OTHER

Identifier Source: secondary_id

UCSF-H411-25738-02

Identifier Type: OTHER

Identifier Source: secondary_id

CDR0000462406

Identifier Type: -

Identifier Source: org_study_id